Skip to main content
. 2023 Mar 22;13:1142661. doi: 10.3389/fonc.2023.1142661

Table 2.

Potential determinants of survival among 1045 patients with untreated HCC.

Total, N=1045 Survival <12 months, n = 810 (%) Survival ≥12 months, n = 235 (%) Mean survival months P value
Age, y
 <60
 ≥60
457
588
368 (80.5)
442 (75.2)
89 (19.5)
146 (24.8)
12.77
12.38
0.047
BCLC stage < .0001
 0/A (very early, early)
 B (intermediate)
 C (advanced)
 D (end stage)
123
96
599
227
35 (28.5)
50 (52.1)
505 (84.3)
220 (96.9)
88 (71.5)
46 (47.9)
94 (15.7)
7 (3.1)
41.33
22.08
8.87
2.64
Etiology 0.001
 HBV
 HCV
 HBV+HCV
 Alcohol use
 Others
544
102
24
155
220
446 (82.0)
70 (68.6)
18 (75.0)
106 (68.4)
170 (77.3)
98 (18.0)
32 (31.4)
6 (25.0)
49 (31.6)
50 (22.7)
11.57
12.74
10.42
16.5
12.37
Child-Pugh class < .0001
 A
 B
 C
469
428
148
291 (62.0)
376 (87.9)
143 (96.6)
178 (38.0)
52 (12.1)
5 (3.4)
20.53
7.26
2.6
MELD score
(n = 984, missing = 61)
 <10
 ≥10
401
583
261 (65.1)
513 (88.0)
140 (34.9)
70 (12.0)
18.42
7.4
< .0001
Serum AFP level (ng/ml)
 <1000
 ≥1000
610
435
417 (68.4)
393 (90.3)
193 (31.6)
42 (9.7)
17.25
5.97
< .0001
ECOG performance status < .0001
 0
 1
 2
 3
 4
550
265
119
65
46
374 (68.0)
220 (83.0)
107 (89.9)
64 (98.5)
45 (97.8)
176 (32.0)
45 (17.0)
12 (10.1)
1 (1.5)
1 (2.2)
17.31
9.49
6.92
2.57
1.98
Encephalopathy
(n = 1042, missing = 3)
0.015
 None
 Mild (confusion)
 Severe (Stupor or coma)
1006
27
9
773 (76.8)
26 (96.3)
9 (100.0)
233 (23.2)
1 (3.7)
0 (0.0)
12.85
4.41
1.44
Ascites
(n = 1037, missing = 8)
< .0001
 None
 Mild
 Moderate to severe
523
297
217
339 (64.8)
257 (86.5)
208 (95.9)
184 (35.2)
40 (13.5)
9 (4.1)
19.64
7.04
3.28
Tumor no. < .0001
 Single
 Multiple
439
606
297 (67.7)
513 (84.7)
142 (32.3)
93 (15.3)
18.48
8.26
Tumor size < .0001
 < 5cm
 ≥ 5cm
279
766
148 (53.0)
662 (86.4)
131 (47.0)
104 (13.6)
15.84
6.07
Portal vein invasion
 No
 Yes
517
528
315 (61.0)
495 (94.0)
202 (39.0)
33 (6.0)
21.13
4.16
< .0001